Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 55Pancreatic Neoplasms 14Colorectal Neoplasms 6Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 4Biliary Tract Neoplasms 4Advanced Pancreatic Cancer 3Stage IV Gastric Cancer With Metastasis 2Recurrence 2Rectal Neoplasms 2Locally Advanced Pancreatic Cancer 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Gastric Cancer 2mCRC 1Surgically-Created Resection Cavity 1Radiation Injuries 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Ductal Adenocarcinoma 1Non-small Cell Lung Cancer Stage â…¡ 1Nasopharyngeal Carcinoma 1NSCLC 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1HER2-positive 1HER-2 Negatived Gastric Cancer 1Gastric Cancer With Positive Exfoliative Cancer Cells 1

Interventions

S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × mCRC × S 1 (combination) × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡